• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

RADIOIMMUNOTHERAPY FOR HEPATIC MICROMETASTASES FROM HUMAN COLON CANCER IN CONGENITALLY ATHYMIC MICE

Research Project

Project/Area Number 12671267
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionTHE JIKEI UNIVERSITY SCHOOL OF MEDICINE

Principal Investigator

YOSHIDA Kazuhiko  Jikei University School of Medicine, Dept. of Surgery, Assistant Professor, 医学部, 助教授 (90191577)

Co-Investigator(Kenkyū-buntansha) FIJIOKA Shuichi  DEPARTMENT OF SURGERY, THE JIKEI UNIVERSITY SCHOOL OF MEDICINE, STAFF, 医学部, 助手 (80287284)
MISAWA Takeyuki  DEPARTMENT OF SURGERY, THE JIKEI UNIVERSITY SCHOOL OF MEDICINE, LECTURE, 医学部, 講師 (50260956)
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 2001: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2000: ¥1,100,000 (Direct Cost: ¥1,100,000)
Keywordsmonoclonal antibody / colorectal cancer / liver metastases / micrometastases
Research Abstract

To determine the efficacy of radio-labeled monoclonal antibody (mAb) for adjuvant setting in colon cancer, we performed a preclinical study using therapeutic doses of I-131 labeled mAb H-15 in a hepatic micormetastases from human colon cancer in congenitally athymic mice.
One hundred twenty mice after one week of intra-splenic injection wore given i. v. injections of either 100, μCi/1μg of I-131 labeled mAb H-15 (low dose) or 500μCi/1μg (high dose). Other 60 mice after one week of intra splenic injection were used as a control arm. The total weight of hepatic metastases of high dose I-131 labeled mAb H-15 group was statistically lower than that of either low dose group or control group. The hepatic metastases/liver and the hepatic metastases/blood ratios of high dose I-131 labeled mAb H-15 group were higher than those of low dose group. The survival rate of high dose I-131 labeled nAb H-15 group was statistically higher than either low dose group or control group.
Other one hundred eighty mice after one week of intrasplenic injection were given i. v. injections of either 500 μ Ci/1 μg of I-131 labeled nAb H-15, 5-day intra peritoneal injection of 20mg/kg of 5-FU and leucovorin (LV) (low concentration), or 5-day intra peritoneal injections of 40mg/kg of 5-FU and LV (high concentration). The total weight of hepatic motastases of I-131 labeled nAb H-15 group was significantly lower than that of either high concentration group of 5 FU/LV or low concentration group of 5 FU/LV. The survival rate of high dose I-131 labeled nAb H-15 group was statistically higher than either high concentration group of 5-FU/LV of low concentration group of 5-FU/LV.
We conclude that I-131 labeled mAb 1H-15 therapy might be an alternative to 5 FU/LV treatment in the adjuvant therapy after complete resection of colon cancer.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi